ライフサイエンスコーパス: stable disease

1 ging survival concomitant with tumor stasis (stable disease).

2 21.7%) met PFS3 (two partial response, three stable disease).

3 n five patients (two partial response, three stable disease).

4 osis; the remaining three (20%) patients had stable disease.

5 trocytoma with clinically and radiologically stable disease.

6 n one or more HRQOL scales despite long-term stable disease.

7 response; the remaining 3 patients (13%) had stable disease.

8 rs had a partial response and 7 patients had stable disease.

9 wo showed partial response, and 13 exhibited stable disease.

10 had dexamethasone added, 4 achieved at least stable disease.

11 four achieved partial response, and four had stable disease.

12 had a partial response, and 10 patients had stable disease.

13 e patient had a partial response and ten had stable disease.

14 rable for patients with tumor regression and stable disease.

15 34 (65%) patients had stable disease.

16 41% (7/17); 6 additional patients (35%) had stable disease.

17 ents with WDLS or DDLS experienced prolonged stable disease.

18 rtial response, and three patients (13%) had stable disease.

19 0% (95% CI 6.8-40.7), and 13 (52%) of 25 had stable disease.

20 ma response criteria, 9 patients (26.5%) had stable disease.

21 l response rate was 41%; 39% of patients had stable disease.

22 r antibiotic treatment and during periods of stable disease.

23 achieved partial responses and 12 (54%) had stable disease.

24 .0% to 40.4%) were observed; 12 patients had stable disease.

25 h a progressive disease from patients with a stable disease.

26 erved in the thymoma cohort; 10 patients had stable disease.

27 Twenty percent (3 of 15) of subjects had stable disease.

28 ed complete response); 27 patients (33%) had stable disease.

29 tum 1 and 15 patients (56%) on stratum 2 had stable disease.

30 Four patients had stable disease.

31 3 patients; 30 (57%) additional patients had stable disease.

32 70 (38%) had stable disease.

33 d CR for almost 2 years, and 3 had transient stable disease.

34 though four (80%) of those patients achieved stable disease.

35 d response criteria), and three instances of stable disease.

36 died during chemotherapy, and all others had stable disease.

37 SCT had disease progression, while 11 showed stable disease.

38 phocytosis; the remaining 5% of patients had stable disease.

39 riteria for renal response and six (40%) had stable disease.

40 teria for cardiac response and six (43%) had stable disease.

41 R2 or FGFR3 translocations); 16 patients had stable disease.

42 te remission, 3.92% partial remission, 1.96% stable disease, 1.96% disease-related death, and 1.96% a

43 disease, had a partial response or prolonged stable disease (10, >/= 6, and >/= 7 months).

44 t response at 4 months (modified RECIST) was stable disease: 12 of 23 (52%) in the ADI-PEG20 group vs

45 ), 10 with partial responses (22%), six with stable disease (13%), eight with progressive disease (18

46 sponse, 5 had minor responses, 6 experienced stable disease, 2 had progressive disease, and 2 withdre

47 responses (3.4%; 90% CI, 1% to 10%); 20 had stable disease; 30 had progressive disease; and seven co

48 l remission (11.5%) and 13 patients achieved stable disease (50%), with an overall disease control ra

49 61% (24 complete and six partial responses); stable disease, 6%; and progressive disease, 2%.

50 artial responses and the third had prolonged stable disease (7.2 months, 24% reduction in tumor size)

51 lete response, 31%) and 20 nonresponders (13 stable disease, 7 progressive disease, 69%).

52 ng a complete response, partial response, or stable disease according to local Response Evaluation Cr

53 s had a partial response and one patient had stable disease according to surface measurements derived

54 often continued during pregnancy to maintain stable disease activity.

55 d as complete response, partial response, or stable disease after 12 weeks, assessed with modified WH

56 Patients who achieved at least stable disease after 4 treatments could receive another

57 If there is stable disease after 6 months of induction chemotherapy

58 Patients with responsive or stable disease after induction treatment, with adequate

59 , 55 patients with inoperable mCRC and prior stable disease after standard chemotherapy were enrolled

60 omes for patients who have achieved at least stable disease after standard first-line therapy.

61 Patients with responsive or stable disease after the first stage were then randomly

62 Stable disease after treatment (hazard ratio, 0.017 vs.

63 5 had confirmed partial responses and 3 had stable disease; all patients had decreases in serum thyr

64 ) (all partial response), with 26% (4 of 15) stable disease and 20% (2 of 15) progressive disease.

65 of 17] partial response), with 18% (3 of 17) stable disease and 30% (5 of 17) progressive disease.

66 n, 33 mo; interquartile range, 20-48 mo) had stable disease and 32 (74.4%; median, 19 mo; interquarti

67 ents with a complete or partial response (or stable disease and clinical benefit) continued to receiv

68 rculation of patients with COPD, during both stable disease and exacerbations.

69 st, pathogen, and resident microbiota during stable disease and exacerbations.

70 In addition, 18 (50%) patients achieved stable disease and none showed progression while on ther

71 Two patients with MM had stable disease and one had normalization of spleen size

72 rs were compared with those of patients with stable disease and progressive disease.

73 (one unconfirmed); eight (38%) patients had stable disease and the remaining two (10%) had progressi

74 py (complete response vs partial response vs stable disease) and primary refractory Hodgkin's lymphom

75 RECIST was 2 with partial response, 36 with stable disease, and 1 with progressive disease (n = 39).

76 as 2.6 months for all tumors, 1.5 months for stable disease, and 1.3 months for progressive disease.

77 artial response, 17.6% minor response, 35.1% stable disease, and 10.8% progressive disease for the en

78 artial response, 17.1% minor response, 48.8% stable disease, and 12.2% progressive disease for nonpan

79 ponse rate, 8%; 95% CI, 2.2% to 25%), 25 had stable disease, and 13 had progressive disease; there we

80 3 mo, 5 patients showed partial response, 26 stable disease, and 17 progressive disease.

81 e considered to have responded, 19 (21%) had stable disease, and 19 (21%) developed diseases progress

82 9 (53%) had a partial response, 3 (18%) had stable disease, and 2 (12%) had progressive disease at t

83 ission, 7 partial, 1 clinical improvement, 4 stable disease, and 3 had progressive disease.

84 tients (91%) had some response, 107 (6%) had stable disease, and 59 (3%) had PD at some point during

85 = 3) response, 1 had a mixed response, 4 had stable disease, and 6 had progressive disease.

86 nalysis, 3 patients had partial response, 49 stable disease, and 6 progressive disease after 6 wk.

87 (27%) had a partial remission, 55 (42%) had stable disease, and 8 patients (6%) had progressive dise

88 artial response, 18.2% minor response, 18.2% stable disease, and 9.1% progressive disease for pancrea

89 esponse (at 250, 400, and 500 mg), 31 showed stable disease, and eight had progressive disease.

90 Twelve patients (21%) had stable disease, and five patients (9%) had primary refra

91 CI 5-29) achieved a partial response, 28 had stable disease, and four had progressive disease.

92 and nine partial responses; 14 patients had stable disease, and nine progressed.

93 with disease progression, two patients with stable disease, and objective response in 24 patients, i

94 ponse rate, 65%; 95% CI, 49% to 81%); 11 had stable disease, and one had progressive disease.

95 cal response to the treatment, with at least stable disease, and only 1 had to stop the therapy after

96 sponse [+minor response for mRECIST/mSWOG]), stable disease, and progressive disease (PD) were 28%, 4

97 Complete and partial response, stable disease, and progressive disease were defined acc

98 iteria are provided for progressive disease, stable disease, and relapse.

99 th progressive disease than in patients with stable disease, and rising concentrations of CA-125 over

100 3%) achieved partial response, six (20%) had stable disease, and seven (23.3%) exhibited KS progressi

101 5% CI 0-26) had a partial response, five had stable disease, and seven had progressive disease.

102 ad a partial response, 14 (67%) patients had stable disease, and six (29%) patients had progressive d

103 a partial response, 12 (75%, 47.6-92.7) had stable disease, and three (19%, 4.1-45.7) had progressiv

104 0 (40%) had a partial response, 13 (52%) had stable disease, and two (8%) had nonevaluable disease.

105 sponses, 15 (65%, 95% CI 42.7-83.6) achieved stable disease, and two (9%, 1.1-28.0) had progressive d

106 Three patients with stable disease are alive without any evidence of progres

107 onse > 36 months; 24 patients (56%) achieved stable disease as best confirmed response.

108 study, was defined as progressive disease or stable disease as best response at any point during chem

109 Complete response, partial response, and stable disease as best response were achieved by 2%, 12%

110 spanning > 2 years, whereas 42 patients had stable disease as the best overall response.

111 Twenty-six patients (60%) had stable disease as the best response, with a disease cont

112 se control (they had a confirmed response or stable disease as their best overall response).

113 Another five patients with prolonged stable disease as their best response remain on study.

114 Stable disease, as defined by Response Evaluation Criter

115 patients (ie, 16 of 30 patients) experienced stable disease at >/= 24 weeks, which yielded a disease

116 abilization, with 3 patients showing ongoing stable disease at 12, 25, and 41 months, respectively.

117 All 10 patients who continued treatment had stable disease at 3 mo.

118 inical benefit rate (objective response plus stable disease at 6 months) among 15 patients treated at

119 ients with a complete or partial response or stable disease at 6 months.

120 Five of 10 evaluable patients had stable disease at 8 wk, and 1 of 11 had a complete remis

121 of 34 treated patients); eight patients had stable disease at EoS, and some experienced complete or

122 With conventional imaging, 31 patients had stable disease at first restaging scans, and 15 of these

123 esponse, 6 had a partial response, and 3 had stable disease at last follow-up.

124 Thirty-one patients with stable disease at week 12 were randomly assigned.

125 h a disease control rate (partial response + stable disease) at 24 weeks of 84%.

126 CI, 1% to 24%) and seven other patients had stable disease by RECIST criteria.

127 Responding patients and those with stable disease continued to be given daily chlorambucil

128 eatment; patients with objective response or stable disease continued treatment until disease progres

129 Chronic hepatitis C may follow a mild and stable disease course or progress rapidly to cirrhosis a

130 tients after HSCT were more likely to have a stable disease course when undergoing HSCT at an early s

131 receiving regular agalsidase-beta dose had a stable disease course, but dose reduction led to worseni

132 owed complete response, partial response, or stable disease (disease control) at 3 mo (95% confidence

133 lioma (LGG) often experience long periods of stable disease, emphasizing the importance of maintainin

134 ns by week 12, with no new lesions seen; (2) stable disease, followed by a slow, steady decline in to

135 BR; complete response, partial response, and stable disease for >/= 24 weeks), and overall survival (

136 n = 7, 4%), with 27 patients (17%) achieving stable disease for >/= 4 months.

137 artial response and eight patients (24%) had stable disease for >/= 6 months.

138 ieved a partial response; eight patients had stable disease for >/= six cycles, seven of whom had sar

139 , unconfirmed, or immune-related response or stable disease for >/=24 weeks) was observed in 65% of p

140 mplete or partial response] plus the rate of stable disease for >/=6 months) and safety.

141 Of 17 evaluable patients, four had stable disease for 12 weeks to 14 months.

142 after a complete response for 38 months and stable disease for 16 months, respectively.

143 ts with MCL, although one patient maintained stable disease for 26 months.

144 Although some patients experienced stable disease for 3 months, none had tumor shrinkage, w

145 partial response, and 11 (34.4%) experienced stable disease for 6 months or longer for a clinical ben

146 rtial response for more than 9 months, 7 had stable disease for 8 weeks to 29 months, and 8 progresse

147 esponse = 7 [13%]) and 10 (19%) patients had stable disease for at least 6 months, for a clinical ben

148 ed solid tumors, with 41% of patients having stable disease for at least 8 weeks.

149 Another patient with low tumor burden had stable disease for four courses.

150 patient with papillary thyroid carcinoma had stable disease for more than 2 years.

151 Two (9%) of 23 patients had stable disease for more than 6 months, and seven patient

152 eved a partial response and seven maintained stable disease for more than 6 months.

153 Partial responders showed stable disease for the duration of the follow-up.

154 Five patients experienced stable disease for three to 24 cycles.

155 d as complete response, partial response, or stable disease (for at least six cycles), analysed by in

156 disease control rate (partial responses plus stable disease) for dasatinib was 43%.

157 nd secondary graft failure, lethal GvHD, and stable, disease-free full donor engraftment using reduce

158 Eight patients experienced stable disease > 3 months, including a patient with meta

159 omplete response or partial response [PR] or stable disease >/= 16 weeks).

160 complete response plus partial response plus stable disease >/= 24 weeks) and progression-free surviv

161 rate (complete response + partial response + stable disease >/= 4 months), 43%.

162 rate (complete response + partial response + stable disease >/= 6 months) was 46%.

163 Stable disease >/= 8 weeks was observed in 42% of patien

164 ively; an additional 50% and 44% experienced stable disease >/= 8 weeks, respectively.

165 ently associated with a greater frequency of stable disease >/=6 months/partial/complete remission [2

166 responses (>/= 5 to >/= 8 months) and three stable diseases >/= 4 months (4 to >/= 8 months) were se

167 s (>/=15 months and >/= 11 months) and eight stable diseases >/= 4 months (median, 8 months [4 to 14.

168 hich was defined as CR, partial response, or stable disease (>/= 16 weeks) by RECIST 1.0 criteria.

169 esulting in partial remission in 2 patients, stable disease in 1 patient, and mixed response in the o

170 enhanced CT revealed partial remission in 5, stable disease in 13, and progressive disease in 7 patie

171 e in 15 (27%), minimal response in 11 (20%), stable disease in 15 (27%), and progressive disease in 1

172 prised a minor response in 2 patients (10%), stable disease in 16 patients (80%; median time to progr

173 MA PET/CT) revealed partial remission in 14, stable disease in 2, and progressive disease in 9 patien

174 nse in 24.6%, partial response in 31.0%, and stable disease in 29.6%.

175 verall response after 3 treatment cycles was stable disease in 3 patients.

176 in five patients (T, n = 3; TC, n = 2), and stable disease in 38 patients (T, n = 27; TC, n= 11), wi

177 4%), increase in 9.1% (control = 37.5%), and stable disease in 54.5% (control = 43.7%).

178 ission in 3, a partial remission in 12 and a stable disease in 6 patients.

179 s was complete response (CR) in 2 (9.5%) and stable disease in 7 (33.3%), yielding a disease control

180 ctive response rate at 12 weeks was 5%, with stable disease in 75% of patients.

181 eatments induced partial tumor regression or stable disease in four of six subjects.

182 Marked activity in one patient and prolonged stable disease in four others suggested a potential subp

183 rearrangement resulted in tumor shrinkage or stable disease in most patients.

184 partial response (PR) in two patients (12%), stable disease in nine patients (56%), and progressive d

185 trol rates (complete or partial remission or stable disease in patients with formerly progressive dis

186 a partial response and 12 vs 14 patients had stable disease in the experimental arm vs mFOLFOX arm.

187 neuroendocrine features, one mixed response (stable disease) in a patient with sarcoma, and one nearl

188 ever, 17 (33%) showed durable (>/= 4 months) stable disease, including seven (47%) of 15 evaluable pa

189 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's ly

190 e disease (k=0.94, percent agreement=97.1%), stable disease (k=0.90, percent agreement=95%), partial

191 nine additional patients (27%) demonstrated stable disease lasting > 24 weeks.

192 Stable disease lasting >/= 12 weeks occurred in four pat

193 Of 7 patients with MM, 4 had stable disease lasting 2-17 months.

194 on had a partial response and the fourth had stable disease lasting 40 weeks.

195 onses in seven patients (15%) and persistent stable disease (lasting 6 months or longer) in nine pati

196 response and an additional 10 patients with stable disease longer than 4 months were observed among

197 reduction in tumor volume) in five dogs and stable disease (<50% change in tumor volume) in four dog

198 30 (26%) of 117 patients had stable disease (median duration 6.0 months, 95% CI 4.7-1

199 edian response duration, 5.3 months); 16 had stable disease (median response duration, 5.3 months).

200 When stratified by responders vs stable disease/minimal response vs progressive disease/N

201 = 234) OS HR, 0.81; 95% CI, 0.59 to 1.11 and stable disease (n = 285) OS HR, 0.76; 95% CI, 0.57 to 1.

202 ponses included partial response (n = 4) and stable disease (n = 57).

203 pulmonary fibrosis (n=32) than in those with stable disease (n=23).

204 , n = 5) and 11 patients were nonresponders (stable disease, n = 9; progressive disease, n = 2).

205 l resolution of symptoms attributed to ECD), stable disease (no change in symptoms attributed to ECD)

206 n of proven or suspected lesion due to ECD), stable disease (no significant change in proven or suspe

207 Complete response, partial response, and stable disease occurred in three (5%), 45 (70%), and 11

208 Prolonged stable disease of at least 4 months was observed in four

209 f 13 patients evaluable after cross-over had stable disease on sunitinib (6 to 27 weeks).

210 nd eight patients with SCLC or carcinoid had stable disease (one remained on study for 13 months).

211 ho were younger than 71 years of age and had stable disease or a marginal, partial, or complete respo

212 Patients in both groups with stable disease or a minor response after 16 weeks were e

213 Sputum from asthmatic patients with stable disease or acute exacerbations was further studie

214 Patients with stable disease or better after four cycles could continu

215 Patients achieving stable disease or better could continue ADI-PEG 20 monot

216 ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extensi

217 st, two induction regimens; and had achieved stable disease or better in the first 100 days after ASC

218 th indolent B-cell non-Hodgkin lymphoma with stable disease or better lasting at least 6 months after

219 months after completion of FR, patients with stable disease or better response received subcutaneous

220 15% achieved partial response or better (76% stable disease or better).

221 All patients achieved stable disease or better, and had decreased tumor volume

222 al infusions every 4 weeks for patients with stable disease or better.

223 nical benefit that extended to patients with stable disease or better.

224 f skin rashes were observed in patients with stable disease or complete remission at 4 wk or longer.

225 isits of SLE patients relative to those with stable disease or healthy controls.

226 e randomisation and received confirmation of stable disease or objective response.

227 Ten patients were enrolled; 8 achieved stable disease or objective responses, whereas 2 had dis

228 , responders lived longer than patients with stable disease or progressive disease.

229 med recurrence in 26 patients whereas 32 had stable disease or remained disease-free.

230 For those with stable disease or response after four cycles, immediate

231 es pemetrexed continuation for patients with stable disease or response to first-line pemetrexed-cont

232 ng progression compared with patients having stable disease or response.

233 In patients who had OR, stable disease, or PD, the median OS was 55-57, 56-74, a

234 In patients who had OR, stable disease, or PD, the median PFS was 26-30, 27-34,

235 ion (as complete response, partial response, stable disease, or progressive disease) used for predict

236 response, partial response, minor response, stable disease, or progressive disease.

237 ignificant to differentiate progressive from stable disease (P = .004, training set; P < .001, valida

238 sets) but not in samples of patients with a stable disease (P = .3, training set; P = .2, validation

239 The median value of mean absorbed dose for stable disease, partial response, and complete response

240 Of 27 patients, stable disease/partial response was noted in 13 patients

241 Those with stable disease per RECIST at 12 weeks were randomly assi

242 disease duration and prolonged survival; the stable disease phase was extended by 88% using mutant Cu

243 hese alleles recapitulates the stochastic bi-stable disease phenotype.

244 Health states included stable disease, progressing disease, hospice, and death.

245 l arms (CAs) included overall response rate, stable disease, progression-free survival (PFS), and ove

246 ients (33.3%) had a best overall response of stable disease (range, 1.2 to 6.7 months), six of whom h

247 e., complete response, partial response, and stable disease) ranged from 29% to 90% for (90)Y radioem

248 Response and stable disease rates were 0% and 58% for monotherapy ver

249 LN4924 to mice bearing AML xenografts led to stable disease regression and inhibition of NEDDylated c

250 nses (>/= 18 months, >/= 7 months) and seven stable disease responses >/= 3 months (median, 9 months;

251 y RECIST: partial response (PR) 21% (17/82), stable disease (SD) 40%, and progression (PD) 39%.

252 Patients achieving at least stable disease (SD) continued bevacizumab 15 mg/kg every

253 artial remissions (PRs), and 5 patients with stable disease (SD) for >/= 6 months resulting in an Int

254 onally, 15 (41%) of 37 patients with MTC had stable disease (SD) for at least 6 months, resulting in

255 ders fulfilled one criterion, and those with stable disease (SD) fulfilled neither.

256 Best response was stable disease (SD) in 10 (23%) patients receiving inter

257 Fourteen patients (38%) had stable disease (SD) that lasted 1.5 to 21 months.

258 te response (CR), partial response (PR), and stable disease (SD) were 47/99 (47%), 39/99 (39%), and 1

259 Another 17 patients (68%) experienced stable disease (SD), 14 of whom (56%) experienced prolon

260 ions showed partial response (PR), 35 showed stable disease (SD), and six showed progressive disease

261 mplete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).

262 responses (>/=300 mg/d) and 15 patients with stable disease (SD), with most responses lasting longer

263 patients with partial response (PR) or with stable disease (SD).

264 te response (CR; neuroblastoma) and five had stable disease (SD).

265 jective responses and 11 patients (28%) with stable disease (SD); the median progression-free surviva

266 There were 35 patients with stable disease (SD, 70%) and a 64% clinical benefit rate

267 complete or partial response [PR] as well as stable disease [SD] >/= 16 weeks).

268 t rate (CBR = complete + partial responses + stable disease [SD] >/= 24 weeks) and safety and pharmac

269 mplete response, 49%; partial response, 38%; stable disease [SD] or local disease progression [DP], 1

270 ete response [CR] or partial response [PR] v stable disease [SD] v progressive disease [PD]), disease

271 sses reflected by CSF biomarkers are robust, stable, disease specific, or even disease stage specific

272 Patients who achieved at least stable disease subsequently received 24 cycles of lenali

273 ficantly higher (P = 0.022) in patients with stable disease than in patients with progressive disease

274 who experienced complete remissions, PRs, or stable disease, the persisting CTLs acquired phenotypic

275 Thirty-five patients (47%) had stable disease: the change in their PSA level ranged fro

276 16 (36%) patients had stable disease; the remaining four (9%) had progressive

277 enance (n = 48), five patients improved from stable disease to partial response, and one patient impr

278 during the first two vaccine courses; 19 had stable disease, two had partial responses, one had a min

279 us, smoking history, and induction response (stable disease v partial response) subgroups.

280 IIA vs IIIB), response to chemoradiotherapy (stable disease vs objective response), delivery of chemo

281 t of complete response, partial response, or stable disease was 16 of 41 patients (39.0%, 95% CI 24.2

282 Stable disease was achieved in 23 patients.

283 Clinical regression or stable disease was achieved in 33 of 77 patients (43%).

284 comparator was 0% versus 4% (P = .925), and stable disease was achieved in 35% versus 17% of patient

285 Stable disease was detected in 19 patients (67.8%) by on

286 Stable disease was maintained in the metronomic groups f

287 In 49% of tumors (19 of 39), stable disease was noted.

288 The confirmed response rate was 7%, and stable disease was observed in 35%.

289 ed average disease control rate (CR, PR, and stable disease) was 86% (95% confidence interval, 78%-92

290 complete response plus partial response plus stable disease) was 94% according to the response evalua

291 ion (complete, partial, or minor response or stable disease) was achieved in 47 patients (87.0%).

292 ed by both objective responses and long-term stable disease, was observed, primarily in patients with

293 d by ORR, although minor tumor responses and stable disease were observed in some patients.

294 Those achieving response or stable disease were randomly assigned at a ratio of 1:1

295 ed on ACH (-0.19 +/- 0.49 mm) yet relatively stable disease when based on PD (0.11 +/- 0.42 mm) and C

296 orter PFS and OS than patients with an OR or stable disease with all 4 scoring systems.

297 med to compare patients with any response or stable disease with patients with PD.

298 sarcomas who achieved objective response or stable disease with prior chemotherapy were randomly ass

299 o patients had a partial response and 26 had stable disease, with no patients progressing on therapy.

300 demonstrated positive radiologic response or stable disease without major adverse events were allowed